
DivestmentAug 4, 2026, 06:27 AM
Revvity to Divest China Immunodiagnostics Business; Q2 EPS $0.48
AI Summary
Revvity, Inc. announced a definitive agreement to divest its Immunodiagnostics business in China (China IDX) for up to $200 million, a business that constituted approximately 6% of its 2025 revenue. Concurrently, the company reported strong second-quarter 2026 financial results, with GAAP EPS from continuing operations of $0.48 on $730 million in revenue. Revvity also raised its full-year 2026 guidance, reflecting positive momentum.
Key Highlights
- Revvity entered a definitive agreement to divest its China Immunodiagnostics business (China IDX) for up to $200 million.
- China IDX represented approximately 6% of Revvity's total revenue in fiscal year 2025.
- Q2 2026 GAAP EPS from continuing operations was $0.48, up from $0.47 in the prior year.
- Q2 2026 revenue was $730 million, compared to $720 million in the same period last year.
- Q2 2026 adjusted EPS from continuing operations was $1.41, up from $1.18 a year ago.
- Diagnostics segment pro forma revenue increased 12% to $371 million in Q2 2026.
- Life Sciences segment pro forma revenue decreased 2% to $359 million in Q2 2026.
- Full-year 2026 pro forma revenue guidance raised to $2.83-$2.86 billion.
- Full-year 2026 pro forma adjusted EPS guidance raised to $5.30-$5.40.
Price Impact
More from RVTY